Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: Lessons from CheckMate 9ER and IMmotion 151-Reference-Cited by-同舟云学术

Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: Lessons from CheckMate 9ER and IMmotion 151

Published:2021-01-20 Issue:2 Volume:27 Page:266-267
ISSN:1078-1552
Container-title:Journal of Oncology Pharmacy Practice
language:en
Short-container-title:J Oncol Pharm Pract

Author:

Khalil Nour¹^ORCID,Sarkis Julien¹^ORCID,Abi Tayeh Georges¹

Affiliation:

1. Department of Urology, Hotel-Dieu de France Hospital, Beirut, Lebanon

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1078155221989424

Reference15 articles.

1. A review of checkpoint inhibitors in the management of renal cell carcinoma

2. Systemic Therapy for Metastatic Renal-Cell Carcinoma

3. Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma – A retrospective study

4. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis;International Journal of Urology;2023-10-15

2. Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance;Cancers;2023-02-19

3. Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy;Cancer Cell International;2022-12-12

4. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy;International Immunopharmacology;2022-12

5. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis;Cancer Treatment Reviews;2021-09